Member access

4-Traders Homepage  >  Shares  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

News SummaryMost relevantAll newsSector news 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

09/08/2011 | 10:10pm US/Eastern

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

React to this article
03:57p ASTELLAS PHARMA : FDA approves Astellas drug for serious fungal infections
03/04 ASTELLAS PHARMA : Patent Issued for Tetrahydroisoquinoline Derivative
03/04 ASTELLAS PHARMA : Data on Non-Small Cell Lung Cancer Described by Researchers at..
03/04 ASTELLAS PHARMA : and BDO Team Up to Offer Health Education at t..
03/04 ASTELLAS PHARMA : Findings from Astellas Pharma, Inc. Yields New Findings on Alz..
03/04 ASTELLAS PHARMA : Recent Research from Astellas Pharma, Inc. Highlight Findings ..
03/04 ASTELLAS PHARMA INC : Antibiotic Croissants; How Matinas Could Revolutionize the..
03/03 ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares - (Under the pro..
03/01 ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 63KB)
02/27 CYTOKINETICS : Joins Global Movement to Raise Awareness for Rare Diseases
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes